3′-Deamino-3′-(2-methoxy-4-morpholinyl)-doxorubicin (FCE 23762): A new anthracycline derivative with enhanced cytotoxicity and reduced cardiotoxicity
- 1 January 1993
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 29 (11) , 1560-1565
- https://doi.org/10.1016/0959-8049(93)90295-q
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Characterization of the toxicity of distamycin derivatives on cancer cell lines and rat heartToxicology, 1992
- In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cellsBritish Journal of Cancer, 1992
- Doxorubicin-Induced Cardiac ToxicityNew England Journal of Medicine, 1991
- Novel anthracycline analogsCancer Treatment Reviews, 1990
- 9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistanceEuropean Journal of Cancer and Clinical Oncology, 1990
- THE BIOCHEMISTRY OF P-GLYCOPROTEIN-MEDIATED MULTIDRUG RESISTANCEAnnual Review of Biochemistry, 1989
- A simple experimental index for the evaluation of inotropic responsesJournal of Pharmacological Methods, 1987
- Measurement of the SαT segment as the most reliable electrocardiogram parameter for the assessment of adriamycin-induced cardiotoxicity in the ratJournal of Pharmacological Methods, 1986
- Intensely potent morpholinyl anthracyclinesJournal of Medicinal Chemistry, 1984
- Evaluation of the Effect of Dopamine and Other Catecholamines on the Electrocardiogram and Blood Pressure of Rats by Means of On-line Biosignal ProcessingJournal of Cardiovascular Pharmacology, 1980